ClinicalTrials.gg
CompletedNCT03432884Updated Apr 24, 2020

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

A Phase 1 interventional study of BGB-3111 and Placebo in Healthy Volunteers, sponsored by BeiGene. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by BeiGene · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Read the detailed description

This is a Two-Part Phase 1 Study.

Part A: This is a randomized, placebo-controlled, double blind, single dose study to evaluate the safety and tolerability of a single oral supratherapeutic dose of zanubrutinib in eight (8) subjects.

Part B: This is a randomized, placebo and positive-controlled, double-blind, 4-way crossover study being conducted in about 28 subjects to investigate the effect of a single therapeutic dose of zanubrutinib, a supratherapeutic dose of zanubrutinib and placebo on cardiac repolarization. Open-label Moxifloxacin (400 mg), a fluoroquinolone broad spectrum antibiotic will be used as a positive control.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Phase 1
  • pharmacokinetics
  • safety
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: All subjects

  1. (BMI) 18 - 33 kg/m2, inclusive.
  2. In good general health as assessed by the Investigator.
  3. Females of non-child bearing potential.
  4. Males without a vasectomy will agree to use required barrier , and will agree to not donate sperm from the time of the first dose of BGB-3111 until ≥ 90 days after the last dose of BGB-3111.
  5. Able to comprehend and willing to sign consent.

Exclusion Criteria: All subjects

  1. Subjects with a history or presence of any clinically significant disease.
  2. Personal or known family history of congenital or acquired long syndrome or cardiovascular disease.
  3. Women of .
  4. History of alcoholism or drug/chemical abuse within 6 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Part A: BGB-3111

    Drug: BGB-3111

  • Placebo comparator
    Part A: Placebo

    Drug: Placebo

  • Experimental
    Part B: BGB-3111, Placebo, and Moxifloxicin

    Drug: BGB-3111 · Drug: Placebo · Drug: Moxifloxacin

Interventions

  • Subjects will receive BGB-3111

  • DrugPlacebo

    Subjects will receive Placebo

  • Subjects will receive Moxifloxicin

    Also known as: Avelox

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of treatment-emergent adverse events (safety and tolerability)

    Incidence of treatment-emergent adverse events reported for zanubrutinib compared with placebo

    Time frame: Up to 8 days

  2. Part B: Corrected QT interval [QTc]

    Evaluate the effects of single doses of zanubrutinib on the corrected QT interval \[QTc\] using the Fridericia correction \[QTcF\]) compared with placebo

    Time frame: Up to 2 days

Secondary outcomes

  1. Part A: PK Parameters

    Plasma concentrations of zanubrutinib to evaluate protocol specified PK parameters

    Time frame: Up to 3 days

  2. Part B: Heart Rate (HR)

    Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on heart rate (HR)

    Time frame: Up to 2 days

  3. Part B: PR Intervals

    Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on PR

    Time frame: Up to 2 days

  4. Part B: QRS Intervals

    Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on QRS Intervals

    Time frame: Up to 2 days

  5. Part B: PK Parameters

    Plasma concentrations of zanubrutinib to evaluate protocol specified PK parameters

    Time frame: Up to 2 days

  6. Part B: Incidence of treatment-emergent adverse events (safety and tolerability)

    Incidence of treatment-emergent adverse events reported for zanubrutinib

    Time frame: Up to 16 days

07

Study locations

1 site
  • Frontage Clinical Services, Inc.
    Secaucus, New Jersey 07094, United States
08

References and documents

Publications

  • Mu S, Darpo B, Tang Z, Novotny W, Tawashi M, Xue H, Willett M, Lin L, Sahasranaman S, Ou YC. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects. Clin Transl Sci. 2020 Sep;13(5):923-931. doi: 10.1111/cts.12779. Epub 2020 Apr 8. PubMed 32144955 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2018
First posted
Feb 14, 2018
StartActual
Jan 25, 2018
Primary completionActual
Apr 16, 2018
CompletionActual
Apr 16, 2018
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03432884
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Jan 25, 2018
Primary completion
Apr 16, 2018
Completion
Apr 16, 2018
Last update
Apr 24, 2020

Study contacts

William Novotny, MD
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion